RECIST working group issues modified guideline for immunotherapy
2 Mar 2017
A recent publication in The Lancet Oncology highlights the development, led by the RECIST Working Group, of iRECIST (immunotherapy Response Evaluation Criteria in Solid Tumours) consensus-based guideline, which addresses the novel characteristics of this new class of anticancer therapeutics, ensuring consistent trial design and data collection.
“There are a growing number of new immune modulators being introduced for cancer therapy, and current trials assessing their efficacy are using a variety of response criteria,” said Dr Lesley Seymour, Director of the Investigational New Drug Program, Canadian Cancer Trials Group and lead author on this paper. “The iRECIST guideline, developed by a multidisciplinary group including academic, commercial and regulatory experts, is based on RECIST 1.1 but incorporates additional criteria allowing for consistent interpretation of tumour progression measurements for immunotherapy treatments.”
Novel immunotherapeutics have been shown, in some patients, to trigger different responses in tumours compared to traditional chemotherapy: they may initially increase in size, followed by shrinkage (pseudoprogression). While the RECIST 1.1 guideline may not capture this unusual pattern of response, iRECIST allows for the delayed responses that occur after ‘pseudoprogression’ to be identified and better characterized. The guideline describes a standard approach to solid tumour measurement and definitions for objective change in tumour size which can be used in immunotherapy clinical trials. In addition, it defines the minimum amount of data to be collected in order to create a data warehouse that can be used to later validate iRECIST.
For more information about iRECIST, please visit the website.
Related News
Meet the new EORTC Board
9 Jul 2024
We are pleased to announce the release of the EORTC 2023 Annual Report
17 Jun 2024
Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group
24 May 2024
Clinical Trials Day 2024: a Q&A on pragmatic clinical trials
20 May 2024
EORTC/EMA workshop suggests an international way forward for treatment optimisation studies
8 May 2024
EORTC’s Participation at the ESTRO Congress 2024
29 Apr 2024
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024